37 completed, 15 terminated, 8 unknown, 6 active not recruiting. 75 Phase 1, 37 Phase 2.
Follow Hydroxychloroquine: new trials by email Literature Review of Hydroxychloroquine trials Research Report on Hydroxychloroquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hydrochloroquinine & Decitabine With Venetoclax in AML Hydroxychloroquine, Venetoclax, Oral Decitabine/cedazuridine - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Rutgers, The State University of New Jersey | 18 | 2026-09-01 | 2026-09-10 |
| Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Hydroxychloroquine, Lipiodol, Placebo - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 93 | 2026-04-01 | 2026-04-16 |
| Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis Hydroxychloroquine Sulfate Tablets, Placebo - Radiation-induced Oral Mucositis | Phase 1 / Phase 2 | Recruiting | Xingchen Peng | 158 | 2024-12-22 | 2025-04-29 |
| HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer Hydroxychloroquine, Sacituzumab Govitecan, Trastuzumab Deruxtecan - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 120 | 2024-01-29 | 2024-03-25 |
| Efficacy and Safety of Different Dose Regimens of Gabapentin for Treating Erythema/Flushing in Rosacea: A Randomized Controlled Trial minocycline combined with hydroxychloroquine, gabapentin 300mg bid, gabapentin 300mg tid - Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic) | Phase 1 | Completed | First Affiliated Hospital of Chongqing Medical University | 50 | 2024-01-05 | 2026-01-05 |
| Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis Hydroxychloroquine, Mesalamine - Ulcerative Colitis (Disorder) | Phase 1 / Phase 2 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 3 | 2022-06-10 | 2025-02-11 |
| COAST Therapy in Advanced Solid Tumors and Prostate Cancer Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir - Prostate Cancer Recurrent, Solid Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 76 | 2022-03-03 | 2026-05-13 |
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss Hydroxychloroquine - Recurrent Pregnancy Loss | Phase 1 | Unknown | Ain Shams University | 70 | 2022-03-01 | 2022-02-14 |
| TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC) Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization - Colorectal Neoplasms Malignant | Phase 1 | Terminated | Abramson Cancer Center at Penn Medicine | 5 | 2022-01-24 | 2024-04-26 |
| Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer Chlorphenesin Carbamate, Hydroxychloroquine - Pancreatic Cancer | Phase 1 | Active not recruiting | Changhoon Yoo | 40 | 2021-11-30 | 2025-04-16 |
| Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer Abemaciclib, Hydroxychloroquine 200 mg, Faslodex - Solid Tumor, Advanced Breast Cancer | Phase 1 | Withdrawn | Medical College of Wisconsin | 2021-10-21 | 2022-12-23 | |
| To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue CPI-613 + Hydroxychloroquine - Sarcoma, Clear Cell | Phase 1 / Phase 2 | Completed | Cornerstone Pharmaceuticals | 16 | 2021-09-01 | 2023-05-24 |
| A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants Nipocalimab, Etanercept, Hydroxychloroquine - Healthy | Phase 1 | Completed | Janssen Research & Development, LLC | 48 | 2021-08-31 | 2025-03-04 |
| Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma Nivolumab (Cohort A), Ipilimumab (Cohort A, B and C), Hydroxychloroquine (HCQ) (Cohort B) - Metastatic Pancreatic Adenocarcinoma | Phase 1 | Completed | Cancer Insight, LLC | 45 | 2021-08-09 | 2025-10-30 |
| Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma Hydroxychloroquine sulfate - Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | Recruiting | West Virginia University | 40 | 2021-07-16 | 2026-04-20 |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Hydroxychloroquine, Vitamins and Minerals, Azithromycin - Covid19, SARS (Severe Acute Respiratory Syndrome) | Phase 1 | Withdrawn | International Brain Research Foundation | 2020-11-01 | 2021-12-07 | |
| A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma Nivolumab, Hydroxychloroquine, Ipilimumab - Melanoma | Phase 1 / Phase 2 | Active not recruiting | Ravi Amaravadi, MD | 41 | 2020-10-21 | 2026-09-21 |
| High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19 Hydroxychloroquine - COVID-19 | Phase 1 | Completed | University of Chicago | 12 | 2020-04-20 | 2023-02-23 |
| Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19 Hydroxychloroquine, Indomethacin, Zithromax Oral Product - COVID-19 | Phase 1 / Phase 2 | Unknown | Perseverance Research Center, LLC | 80 | 2020-04-16 | 2020-07-01 |
Showing 20 of 75. Sign in to see all of them.
COVID-19 (4) · Melanoma (4) · Pancreatic Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Multiple Myeloma (3) · Adenocarcinoma (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Coronavirus Infections (2) · Gastrointestinal Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Neoplasms (2) · Prostatic Neoplasms (2)
Abramson Cancer Center at Penn Medicine (11) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (2) · Peng Wang, MD PhD (2) · The University of Texas Health Science Center at San Antonio (2) · University of Medicine and Dentistry of New Jersey (2) · University of Pittsburgh (2) · University of Utah (2) · Ain Shams University (1) · Alison Sehgal, MD, MS (1) · Amer Zureikat (1) · BioLineRx, Ltd. (1) · BioXcellerator (1) · Brigham and Women's Hospital (1) · Cairo University (1)
United States (54) · China (3) · Belgium (2) · France (2) · Netherlands (2) · Australia (1) · Canada (1) · Colombia (1) · Norway (1) · Singapore (1) · South Korea (1) · Thailand (1) · United Kingdom (1)
Ravi Amaravadi, MD (5) · Peng Wang, MD, PhD (2) · Peter O'Dwyer, MD (2) · Alfredo Hernandez-Ruiz, MSc (1) · Alison Sehgal, MD (1) · Angela DeMichele, MD (1) · Anthony Joshua, MBBS(Hons) PhD (1) · Bart Neyns, MD PhD (1) · Bayard Powell, MD (1) · Bonnie S Slovis, MD (1) · Brian Boone, MD (1) · Changhoon Yoo, MD, PhD (1) · Conan Kinsey, MD (1) · Dan Vogl, MD (1)
PMID 10632428, PMID 19439078, PMID 21112094, PMID 21718553, PMID 21871597, PMID 22002012, PMID 22878749, PMID 23942472, PMID 24581729, PMID 24991834, PMID 24991840, PMID 24995856, PMID 25653897, PMID 25681385, PMID 26371706, PMID 27100512, PMID 28192114, PMID 29929491, PMID 30144422, PMID 30603055, PMID 31120501, PMID 31299246, PMID 31401903, PMID 32360760, PMID 32989925, PMID 33416261, PMID 34840653, PMID 35156519, PMID 35385049, PMID 35552447, PMID 35929658, PMID 36875717, PMID 39136023, PMID 39681269, PMID 39710117, PMID 39865083, PMID 39866949, PMID 42284543, PMID 9344498
P30CA072720 (4), U01CA132194 (2), 1ZIAHL002541-21 (1), 2008 (1), 2019 (1), P30CA012197 (1), P30CA016059 (1), P30CA069533 (1), U01CA062475 (1), UM1CA081457 (1), UM1CA186716 (1)